ArticleJournal for immunotherapy of cancer2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial.Journal for immunotherapy of cancer · 2026Trial
- Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer.Immuno-oncology technology · 2026Article
- Article
- When Selectivity Increases Uncertainty: Context-Dependent Pharmacology in Antibody Drug Development.Clinical and translational science · 2026Article
- Periodontitis-Induced Immune Reprogramming: Implications for Cancer Immunotherapy Response.Biomedicines · 2026Review
- CD4Nature medicine · 2026Article
- Plying potency assays for immunotherapy of solid tumors.Frontiers in immunology · 2026Review
- Serous Papillary Adenofibroma Cyst of the Ovary in a Young Woman: Case Report and Literature Review.Life (Basel, Switzerland) · 2025Review
- From innate-like to innate: the next wave of off-the-shelf CAR immunotherapies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Cancer immunotherapy has radically changed the management of several malignancies, and dozens of agents have been approved in the past 15 years. While these advances have changed the field, many challenges lie ahead and must be addressed if we are to optimize the management of cancer with these approaches. A more comprehensive understanding of the mechanisms of action, toxicity, and resistance is needed to guide the next decade of cancer immunotherapy development. To this end, members of the Society for Immunotherapy of Cancer met and identified challenges and opportunities to improve cancer immunotherapy by focusing on the mechanisms by which the specific agents work, the mechanisms of how they cause adverse effects, and the mechanisms of resistance that limit the effectiveness of these agents. The priorities of this effort were to (1) level set by describing the state of the field; (2) describe what is known about how these agents work, fail to work, and cause side effects as well as the key knowledge gaps in these areas and associated challenges for addressing them; (3) provide a patient perspective to highlight the importance of this work to the community most affected; (4) look ahead to the future by identifying and describing prioritized opportunities that the field may focus on to expand the knowledge base of the field and optimize the management of cancer with immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.